drugset / Trial / NCT03497702
Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is an exploratory interventional study that initiates chemotherapy with letrozole in patients with estrogen receptor positive/HER2-negative breast cancer preoperably.
Timeline
- Start
- 2017-05-08
- Primary completion
- 2023-11
- Completion
- 2024-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 600 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 60 mg/m2 | Intravenous |
| Subject | Letrozole | Other / unclassified | 2.5 mg | — |
| Subject | Leuprolide | Other / unclassified | 3.75 mg | Subcutaneous |